Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone.

JBMR plus·2025
Same author

Acquired Osteomalacia Associated with Autoantibodies against PHEX.

The New England journal of medicine·2025
Same author

Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia.

Journal of the Endocrine Society·2024
Same author

FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis.

JACC. Advances·2024
Same author

A Novel Pathogenic Variant in Fibroblast Growth Factor 23 outside the Furin-Recognizing RXXR Motif in an Autosomal Dominant Hypophosphatemic Rickets Patient.

Hormone research in paediatrics·2024
Same author

The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia.

JBMR plus·2023

Related Experiment Video

Updated: Dec 20, 2025

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.5K

[Endocrine disorders and osteoporosis].

Yuka Kinoshita

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |November 5, 2015
    PubMed
    Summary

    Secondary osteoporosis, a bone density loss condition, results from underlying diseases or medications. Endocrine disorders frequently cause this condition, which bisphosphonates can help manage alongside treating the root cause.

    Area of Science:

    • Endocrinology
    • Bone Biology
    • Pharmacology

    Context:

    • Secondary osteoporosis is a significant health issue characterized by reduced bone mass and increased fracture risk.
    • It arises from various underlying medical conditions or medication side effects.
    • Endocrine system disorders are frequently implicated in the development of secondary osteoporosis.

    Purpose:

    • To summarize the causes and management of secondary osteoporosis.
    • To highlight the role of endocrine disorders in bone metabolism disruption.
    • To identify effective pharmacological interventions for fracture prevention.

    Summary:

    • Secondary osteoporosis stems from hormonal imbalances in endocrine diseases like hyperparathyroidism, hyperthyroidism, hypogonadism, growth hormone deficiency, Cushing's syndrome, and anorexia nervosa.

    More Related Videos

    Osteoclast Derivation from Mouse Bone Marrow
    06:17

    Osteoclast Derivation from Mouse Bone Marrow

    Published on: November 6, 2014

    24.7K
    A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
    11:47

    A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

    Published on: June 8, 2014

    12.0K

    Related Experiment Videos

    Last Updated: Dec 20, 2025

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
    06:00

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

    Published on: September 13, 2017

    7.5K
    Osteoclast Derivation from Mouse Bone Marrow
    06:17

    Osteoclast Derivation from Mouse Bone Marrow

    Published on: November 6, 2014

    24.7K
    A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
    11:47

    A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

    Published on: June 8, 2014

    12.0K
  • These hormonal disturbances disrupt the normal function of bone cells (osteoblasts, osteocytes, osteoclasts), leading to abnormal bone remodeling.
  • Bisphosphonates are recommended as a primary treatment for preventing fractures in secondary osteoporosis patients, concurrent with addressing the underlying condition.

    • Impact:

    • Provides a concise overview of secondary osteoporosis etiology and pathophysiology.
    • Emphasizes the importance of managing endocrine disorders to prevent bone loss.
    • Establishes bisphosphonates as a key therapeutic strategy for fracture risk reduction in this patient population.